Advanced or Recurrent Solid Tumors Treated With SHetA2

Part of paid clinical trials in Oklahoma City, Oklahoma.

Sponsor
University of Oklahoma
Study ID
NCT04928508
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumor, Adult

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • OK-1 — DRUG
    OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated: 5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg

Study Details

The purpose of this research is to test the safety of the study drug (OK-1) and see what effects (good and bad) this drug has on patients with recurrent solid tumors.

Key Dates

Start date
Jul 27, 2022
Status verified
Mar 2026
Primary completion
May 31, 2026
Completion
Jun 30, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: OK-1 capsule
    OK-1 (oral, BID) within a 21-days cycle

Primary Outcome Measure

Number of dose-limiting toxicities of treatment with OK-1 [ Time Frame: 21 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stephenson Cancer CenterOklahoma CityOklahoma73104
Ingrid Block
[email protected]
405-271-8777
Lead Gynecology Oncology Nurse
[email protected]
1-405-271-8777
Debra Richardson, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Oklahoma City, OK

By research site
Stephenson Cancer Center· Oklahoma City, OK

Related Studies